ACW raises an addtional $3.55m under a Shortfall Placement
Filed with ASX · · 2 pages · English
Sydney,10 February 2021. Actinogen Medical ASX: ACW (‘ACW’ or ‘the Company’) is pleased to announce that it has successfully completed a ~$3.55 million shortfall placement (Shortfall Placement), in accordance with the terms of the entitlement offer (Entitlement Offer) that closed on Tuesday, 10 November 2020. The Company placed ordinary shares to professional and sophisticated investors in respect
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Resignation of Dr Bill Ketelbey as Chief Executive Officer
- FDA Grants ACW Rare Paediatric Disease Designation in FXS
- Completion of Entitlement Offer
- Actinogen files new patent applications
- FDA IND Update
Later from Actinogen Medical
- Actinogen appoints Dr Steven Gourlay as CEO
- Actinogen CEO assumes Managing Director position
- Strategic Update & Teleconference Call Notification
- Response to ASX Price Query
- Actinogen Ethics Committee approval for XanaMIA study
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical